-
11.发明授权
公开(公告)号：KR101305800B1
公开(公告)日：2013-09-06
申请号：KR1020090117364
申请日：2009-11-30
Applicant: 한국생명공학연구원 , 한남대학교 산학협력단
Abstract: 본 발명은 글루타메이트 디카르복실라아제 활성을 갖는 신규한 미생물 락토바실러스 BFC90 (KCTC 11584BP)와 락토바실러스 BFC110(KCTC 11601BP ) 균주를 이용하여 아미노부틸산을 제조하는 방법에 관한 것으로서, 본 발명의 락토바실러스 균주를 사용하면 고농도의 아미노부틸산을 생산할 수 있다.
아미노부틸산, 글루타메이트 디카르복실라아제, 락토바실러스-
公开(公告)号：KR1020130074171A
公开(公告)日：2013-07-04
申请号：KR1020110142083
申请日：2011-12-26
Applicant: 한남대학교 산학협력단
CPC classification number: A61L24/04 , A61F2/28 , A61L24/0015 , A61L24/0052 , A61L24/0063
Abstract: PURPOSE: A bone cement for having a sustained drug release behavior is provided to resolve a problem of a drug effect not lasting for a predetermined time by allowing a fast initial burst of 10 to 20% of the drug actually included (burst: a concentration of a drug at a localized region being reduced to a treating range or less in time). CONSTITUTION: A bone cement comprises a drug, a bone cement matrix, and an amphiphilic additive. The amphiphilic additive is at least one selected from the group consisting of polyethylene oxide-polypropylene oxide copolymers, polyethylene oxide-polylactic acid copolymer, polyethylene oxide-polylactic acid copolymers, poly (ethylene oxide)-poly lactic glycolic acid copolymers, polyethylene oxide-polycaprolactone copolymers, polyethylene oxides, polyvinyl alcohols, polyoxyethylene alkyl ethers, polyoxyethylene Kester oil derivative, polyoxyethylene sorbitan fatty acid esters, and polyoxyethylene stearates. 0.1 to 40 parts by weight of the amphiphilic additive is included with respect to 100 parts by weight of the bone cement matrix. The drug is at least one selected from antibiotics, anticancer drugs, antimicrobial agents, antiphlogistics, and analgesics. [Reference numerals] (AA) Mix; (BB) Silicone mold; (CC) Drug containing amphiphilic additives/bone cement
Abstract translation: 目的：提供具有持续药物释放行为的骨水泥，通过允许实际包括的药物的10至20％的快速初始爆发来解决不持续预定时间的药物作用的问题（爆发：浓度 在局部区域的药物在时间上减少到治疗范围或更少）。 构成：骨水泥包括药物，骨水泥基质和两亲性添加剂。 两亲性添加剂是选自聚环氧乙烷 - 聚环氧丙烷共聚物，聚环氧乙烷 - 聚乳酸共聚物，聚环氧乙烷 - 聚乳酸共聚物，聚（环氧乙烷） - 聚乳酸乙醇酸共聚物，聚环氧乙烷 - 聚己内酯 共聚物，聚环氧乙烷，聚乙烯醇，聚氧乙烯烷基醚，聚氧乙烯Kester油衍生物，聚氧乙烯山梨糖醇酐脂肪酸酯和聚氧乙烯硬脂酸酯。 相对于100重量份的骨水泥基质，包含0.1〜40重量份的两亲性添加剂。 该药物是选自抗生素，抗癌药，抗微生物剂，消炎药和止痛剂中的至少一种。 （标号）（AA）混合; （BB）硅胶模具; （CC）含有两亲性添加剂/骨水泥的药物
-
公开(公告)号：KR101082895B1
公开(公告)日：2011-11-11
申请号：KR1020080126507
申请日：2008-12-12
Applicant: 한남대학교 산학협력단
Abstract: 본발명은주사주입이용이한미세입자필러시스템에관한것으로서, 보다상세하게는고분자미세입자를, 수용액상에서온도에따라상전이현상(졸-겔특성)을가지는고분자용액을사용함으로써, 저온에서졸(sol) 상으로미세입자와고분자용액이균일하게혼합되고상온(또는상온근처의온도)에서겔(gel) 상을이루어, 상기미세입자가고분자겔 내에균일하게분산되며, 이미세입자/고분자겔이체내에균일하게주입되고안정하게부피를유지할수 있는졸-겔특성을가지는주사주입제에관한것이다. 본발명에따르면, 미세입자의일그러짐, 미세입자와용액의불균일한혼합등의기존의주사주입제의문제점을개선할수 있을뿐만아니라, 다양한물질로제조되어진미세입자를균일하게주사주입할수 있어다양한의약학분야에적용할수 있는효과가있다.
-
14.发明公开글루타메이트 디카르복실라아제 활성을 갖는 신규 락토바실러스 균주 및 이를 이용한 아미노부틸산 제조방법 有权使用乳杆菌SP的氨基丁酸生产方法 含有GLUTAMATE DECBOXYLASE的BFC 90和BFC 110
公开(公告)号：KR1020110060696A
公开(公告)日：2011-06-08
申请号：KR1020090117364
申请日：2009-11-30
Applicant: 한국생명공학연구원 , 한남대학교 산학협력단
Abstract: PURPOSE: A novel microorganism Lactobacillus strain and a method for preparing amino butyric acid through fermentation and enzyme method are provided. CONSTITUTION: A Lactobacillus BFC90(KCTC 11584BP) or Lactobacillus BFC11(KCTC 11601BP) has glutamate dicarboxylase activity. A method for preparing amino butyric acid comprises: a step of culturing Lactobacillus BFC90(KCTC 11584BP) or Lactobacillus BFC11(KCTC 11601BP); and a step of collecting culture strain and contacting with glutamic acid or glutamate. The method further comprises a step of contacting the strain with a coenzyme.
Abstract translation: 目的：提供一种新型微生物乳杆菌菌株和通过发酵制备氨基丁酸的方法和酶法。 构成：BFC90（KCTC 11584BP）或BFC11乳杆菌（KCTC 11601BP）具有谷氨酸二羧酸酶活性。 制备氨基丁酸的方法包括：培养Bact90乳杆菌（KCTC 11584BP）或BFC11乳杆菌（KCTC 11601BP）的步骤; 并收集培养菌株并与谷氨酸或谷氨酸接触的步骤。 该方法还包括使菌株与辅酶接触的步骤。
-
公开(公告)号：KR101875587B1
公开(公告)日：2018-07-09
申请号：KR1020170028301
申请日：2017-03-06
Applicant: 한남대학교 산학협력단
CPC classification number: A61L27/54 , A61K38/18 , A61K38/39 , A61L27/18 , A61L27/20 , A61L27/56 , A61L27/58 , A61L2300/252 , A61L2300/414 , A61L2300/602 , A61M31/002
Abstract: 본발명은그물구조를가지는구조체, 및비대칭구조를가지는미세다공성막층으로이루어진복합막구조의기관재생유도관과이의제조방법에관한것으로서, 본발명에따른기관재생유도관은기관을재생하는동안외부의하중에견딜수 있는기계적물성을지녀체 내이식시기관협착이일어나지않으며, 기관재생유도관의내부와외부가비대칭미세다공구조를가짐으로써산소와자양분이잘 전달되며연골과같은주변조직과잘 결합하게도와주는역할과함께전달된산소와자양분을통해섬모상피층과같은주변조직이잘 점착되어효과적으로기관재생에기여할수 있다. 또한, 본발명에따른기관재생유도관은성장인자와단백질을탑재시킬수 있으며, 상기탑재된성장인자와단백질이서방형방출되면서기관재생에중요한섬모상피세포로효과적으로증식, 분화되는효과를가진다.
-
Patent Agency Ranking
公开(公告)号：KR101628707B1
公开(公告)日：2016-06-10
申请号：KR1020140065366
申请日：2014-05-29
Applicant: 한남대학교 산학협력단
IPC: A61K47/48 , A61K31/704 , A61P27/16
Abstract: 본발명은전하를띠는약물과이온성화합물을이용하여다중이온컴플렉스시킨난청치료용서방형약물전달시스템과이의제조방법에관한것이다. 본발명에따른약물과이온성화합물을이용하여다중이온컴플렉스시킨난청치료용서방형약물전달시스템은중이강에적용시 초기 (24시간이내)에빠르게방출되지않고, 서방형방출거동 (일주일이상)을보여중이강으로의약물의효과적인전달이가능하다. 또한, 본발명에따른다중이온컴플렉스시킨서방형약물전달시스템은점착성 (adhesiveness)을가져중이강부위에적용시, 번거롭고어려운과정없이도입부위에안정하게존재하며, 상기다중이온컴플렉스된수용성약물이중이강부에머무를수 있는환경을제공하며, 중이강에도입된제제로부터약물이중이의정원창을통해지속적으로내이로공급되어내이세포 (유모세포)를보호할정도의농도를지속적으로유지하며일정시간후 서서히체내로흡수되어임상의에게는치료의수월성을, 환자에게는빠른치유에의한고통경감효과를부여할수 있다.
-
公开(公告)号：KR1020160047634A
公开(公告)日：2016-05-03
申请号：KR1020140143358
申请日：2014-10-22
Applicant: 한남대학교 산학협력단
CPC classification number: A61L27/56 , A61F2/04 , A61F2002/043 , A61L27/14 , A61L27/24 , A61L27/40 , A61L27/52 , A61M16/0402
Abstract: 본발명은평균다공크기가 10~100 nm인내표면, 평균다공크기가 10 ㎛이상인컬럼형태의중간층, 및평균다공크기가 50~200 ㎛인외표면으로구성된튜브형태의기관재생용매트릭스; 및상기매트릭스표면에형성된점막세포유도층을포함하는것을특징으로하는점막재생이가능한기관재생용매트릭스및 이의제조방법에관한것이다. 본발명에따른튜브형태의기관재생용매트릭스는내표면, 컬럼형태의중간층및 외표면으로구성되는튜브전체가다공성구조를가지며, 그굵기와길이를자유롭게조절가능하여다양한형태의손상된조직과상처에적용이용이하고, 체내에이식시, 지지체로사용된고분자재료의물성에의해외부에서가해지는압력에견디며기관재생을위한공간을확보할수 있으며, 정상기관과유사한골격을유지하여기관의재협착을방지할수 있는충분한물성을가지면서기관이재생된후에는자연스럽게분해되는성질을지녀매트릭스제거를위한위험한재수술이필요없게된다.
Abstract translation: 本发明涉及一种用于支气管再生的管状基质，其包括平均孔径为10-100nm的内表面，平均孔径为10μm以上的中间层，以及平均孔径 为50-200μm，涉及能够再生含有形成在基质表面的粘液细胞诱导层的粘膜的支气管再生的基质及其制备方法。 根据本发明的用于支气管再生的管状基质在整个管中具有多孔结构，包括内表面，中间层的柱形状和外表面。 基体的厚度和尺寸可自由调节，使基质容易应用于各种损伤的组织和疤痕。 当被移植到体内时，由于用作支持物的聚合物的物理性质，基质可以承受从外部施加的压力并确保用于支气管再生的空间。 此外，该基体具有足以通过保持与正常支气管相似的结构来防止支气管再次感觉的物理性质，并且在支气管再生后天然地降解，因此不需要危险的再次手术去除基质。
-
公开(公告)号：KR1020130085600A
公开(公告)日：2013-07-30
申请号：KR1020120006471
申请日：2012-01-20
Applicant: 한남대학교 산학협력단
CPC classification number: A61K9/0029 , A61K47/593 , A61K47/6903 , A61K48/0058 , A61K48/0075
Abstract: PURPOSE: An injectable polymer formulation including a specific gene complex is provided to have a passive urinary incontinence treatment effect with a polymer mixture matrix including micro particles in the early stage of injection, and to induce stable and continuous production/emission by including a specific gene complex capable of regenerating damaged sphincter, blood vessel and nerve near urethra. CONSTITUTION: An injectable polymer formulation includes a gene complex and a polymer mixture matrix. The gene complex is sustained-released from the polymer mixture matrix. The gene complex includes cationic polymer and plasmid DNA (pDNA) capable of producing a bioactive substance by being introduced into the cell. The bioactive substance is continuously produced and released from the introduced cell. [Reference numerals] (AA) Normal group; (BB) Control group; (CC) Comparative example 1; (DD) Example 1
Abstract translation: 目的：提供包含特定基因复合物的可注射聚合物制剂，以在注射早期阶段与包含微粒子的聚合物混合物基质进行被动尿失禁治疗，并通过包括特定基因诱导稳定和连续的生产/排放 复合体能够再生损伤的括约肌，血管和尿道附近的神经。 构成：可注射聚合物制剂包括基因复合物和聚合物混合物基质。 基因复合物从聚合物混合物基质中持续释放。 基因复合物包括阳离子聚合物和能够通过引入细胞而产生生物活性物质的质粒DNA（pDNA）。 生物活性物质从引入的细胞中连续生产和释放。 （附图标记）（AA）正常组; （BB）对照组; （CC）比较例1; （DD）实施例1
-
公开(公告)号：KR1020110075618A
公开(公告)日：2011-07-06
申请号：KR1020090132113
申请日：2009-12-28
Applicant: 한남대학교 산학협력단
CPC classification number: A61L27/54 , A61K9/0019 , A61K9/0024 , A61K31/381 , A61K31/4162 , A61L27/58 , A61K2300/00
Abstract: PURPOSE: A porous fine particle filler system is provided to uniformly disperse fine particles in polymer gel and to stably maintain volume. CONSTITUTION: An injection agent contains biodegradable polymer fine particles and a temperature sensitive phase transition biocompatible polymer solution. The biodegradable polymer fine particle is porous particles. The temperature sensitive phase transition biocompatible polymer solution is a polyethylene oxide(PEO)-polypropylene oxide(PPO) copolymer, a polyethylene oxide(PEO)-polylactic acid(PLA) copolymer, or a polyethylene oxide(PEO)-polyglycolic lactic acid(PLC) copolymer. The solution contains alginic acid, hyaluronic acid, carboxymethyl cellulose, dextran, collagen, gelatin, or elastin.
Abstract translation: 目的：提供多孔细颗粒填充体系，使细颗粒均匀分散在聚合物凝胶中并稳定地保持体积。 构成：注射剂含有可生物降解的聚合物细颗粒和温度敏感相变生物相容性聚合物溶液。 可生物降解的聚合物细颗粒是多孔颗粒。 温度敏感相变生物相容性聚合物溶液是聚环氧乙烷（PEO） - 聚环氧丙烷（PPO）共聚物，聚环氧乙烷（PEO） - 乳酸（PLA）共聚物或聚环氧乙烷（PEO） - 聚乙醇酸乳酸 ）共聚物。 该溶液含有藻酸，透明质酸，羧甲基纤维素，葡聚糖，胶原，明胶或弹性蛋白。
-
公开(公告)号：KR1020100067909A
公开(公告)日：2010-06-22
申请号：KR1020080126507
申请日：2008-12-12
Applicant: 한남대학교 산학협력단
CPC classification number: A61K47/34 , A61K9/0019 , A61K47/36 , A61K47/42 , A61K2121/00 , Y10S514/97
Abstract: PURPOSE: A microparitcle filler system which is easy to inject is provided to improve stability of initial injection skin and to uniformly inject microparticles. CONSTITUTION: An injection agent contains polymer particles, thermosensitive phase transition biocompatible polymer solution. The biocompatible polymer is polyethylene oxide(PEO)-polypropyleneoxide(PPO) copolymer, polyethyleneoxide(PEO)-polylactic acid(PLA) copolymer, polyethyleneoxie(PEO)-polyglycholic lactic acid(PLGA) copolymer, or polyethyleneoxide(PEO)-polycaprolactone(PCF) copolymer. The biocompatible polymer solution is alginic acid, hyaluronic acid, carboxymethyl cellulose, dextran, collagen, gelatin, or elastin. The injection is used for treating urinary incontinence or as a prosthetic filler for plastic surgery.
Abstract translation: 目的：提供易于注射的微细填充体系，以提高初始注射皮肤的稳定性和均匀注射微粒。 构成：注射剂含有聚合物颗粒，热敏相变生物相容聚合物溶液。 聚氧化乙烯（PEO） - 聚环氧丙烷（PPO）共聚物，聚环氧乙烷（PEO） ）共聚物。 生物相容性聚合物溶液是藻酸，透明质酸，羧甲基纤维素，葡聚糖，胶原，明胶或弹性蛋白。 注射用于治疗尿失禁或作为整形手术的假体填料。
-
-
-
-
-
-
-
-
-
Search Results
56
records
(took 0.031 seconds)
